Xbac 60ml

Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below.Uncomplicated Urinary Tract Infections (Acute Cystitis): Ciprofloxacin is indicated for the treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus.

Because fluoroquinolones, including Ciprofloxacin, have been associated with serious adverse reactions and for some patients uncomplicated UTI (acute cystitis) is self-limiting, reserve Ciprofloxacin for treatment of uncomplicated UTIs (acute cystitis) in patients who have no alternative treatment options.

Complicated Urinary Tract Infections, And Acute Uncomplicated Pyelonephritis: Ciprofloxacin is indicated for the treatment of complicated urinary tract infections (cUTI) caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, or Pseudomonas aeruginosa and acute uncomplicated pyelonephritis(AUP) caused by Escherichia coli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin and other antibacterialdrugs, Ciprofloxacin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued.

As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.

4-Quinolone preparations, Anti-diarrhoeal Antimicrobial drugs

Ciprofloxacin is a synthetic broad-spectrum antimicrobial agent for intravenous administration. The bactericidal action of Ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Adult Dose (Oral):

Urinary Tract infection:

• Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days;
• Severe/Complicated: 500 mg twice daily for 7 to 14 days;

Chronic Bacterial Prostitis: 500 mg twice daily for 28 days;

Lower Respiratory Tract infection:

• Mild/Moderate: 500 mg twice daily for 7 to 14 days,
• Severe/Complicated: 750 mg twice daily for 7 to 14 days;

Acute Sinusitis: 500 mg twice daily for 10 days;

Skin and Skin Structure infection:

• Mild/Moderate: 500 mg twice daily for 7 to 14 days,
• Severe/Complicated: 750 mg twice daily for 7 to 14 days,

Bone and joint infection:

• Mild/Moderate: 500 mg twice daily for 4 to 6 weeks,
• Severe/Complicated: 750 mg twice daily for 4 to 6 weeks,

Intra Abdominal Infection: 500 mg twice daily for 7 to 14 days,

Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days,

Typhoid Fever: 500 mg twice daily for 10 days,

Urethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose.

For IV infusion:

Urinary Tract Infection:

• Mild to Moderate: 200 mg 12 hourly for 7-14 days;
• Severe or Complicated: 400 mg 12 hourly for 7-14 days;

Lower Respiratory Tract infection:

• Mild to Moderate: 400 mg 12 hourly for 7-14 days;
• Severe or Complicated: 400 mg 8 hourly for 7-14 days;

Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days;

Skin and Skin Structure:

• Mild to Moderate: 400 mg 12 hourly for 7-14 days;
• Severe or Complicated: 400 mg 8 hourly for 7-14 days;

Bone and Joint Infection:

• Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks;
• Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks;

Intra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days;

Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for 10 days:

Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days.

Children and adolescents:

RTI & GI infections:

• Neonate: 15 mg/kg twice daily,
• Child (1 month -18 years): 20 mg/kg (max 750 mg) twice daily;

UTI:

• Neonate: 10 mg/kg twice daily,
• Child (1 month -18 years): 10 mg/kg (max 750 mg) twice daily

Pseudomonal lower respiratory tract infection in cystic fibrosis:

• Child (1 month -18 years): 20 mg/kg (max 750 mg) twice daily;

Anthrax (treatment & post exposure prophylaxis):

• Child (1 month-18 years): 20 mg/kg (max 750 mg) twice daily.

Increased plasma levels of theophylline have been observed following concurrent administration with Ciprofloxacin. Ciprofloxacin suspension should not be administered within 4 hours of medications containing magnesium, aluminium, calcium or iron salts as interference with absorption may occur.

Ciprofloxacin is contra-indicated in patients who have shown hypersensitivity to Ciprofloxacin or other quinolones.

Ciprofloxacin is generally well tolerated. The most frequently reported side effects are nausea, diarrhea and rash.